Objective: Regenerative medicine seeks to stall or to reverse the pathologic consequences of chronic diseases. Many people with diabetes have peripheral arterial disease (PAD), which increases their already high risk of major amputation. Cellular therapies are a promising regenerative medicine approach to PAD that can be used to focally inject regenerative cells to endangered tissue beds. Mesenchymal stem cells (MSCs) are known to promote tissue regeneration through stromal support and paracrine stimulation of new blood vessels (angiogenesis). Whereas little is known about human diabetic MSCs (dMSCs), particularly those from patients with PAD, dMSCs have a limited expansion capacity but can be improved with human platelet lysate (PL) supplementation. PL is rich in many growth factors, including epidermal growth factor (EGF), which is known to be important to cell proliferation and survival signaling pathways. We hypothesize that dMSCs have a reversible defect in EGF receptor pathways. The objective of this work was to test this hypothesis using dMSCs from PAD patients.
Diabetes affects 30 million people in the United States. 1 Diabetes is a chronic disease that limits the effectiveness of one's innate reparative capacity, accelerating diseases of aging, including peripheral arterial disease (PAD). According to the American Heart Association, 12% to 20% of the U.S. population older than 65 years has PAD, but diabetic patients have an incidence of 30% by the age of 50 years. 2 In general, patients with PAD have a low overall incidence of major amputation, but this is not so in diabetes. 3 Diabetic patients have an 8-fold increase in major amputation compared with nondiabetics, and this increases 15-fold with smoking. 4 On pathologic examination, PAD patients have profound defects in the vascular supply of PAD muscle with subsequent ischemic damage to the skeletal muscle. 5 Diabetic patients also have a limited capacity for neovascularization because of insufficient growth of new (angiogenesis) and failure to grow existing collateral arteries. Thus, diabetic patients with PAD are in urgent need of regenerative therapies.
Despite the initial gloom about the quality of autogenous cells from patients with cardiovascular disease, 6 a number of clinical trials have shown us that cellular therapies are a particularly promising regenerative approach to PAD. [7] [8] [9] However, the benefits are less obvious when results are restricted to controlled trials. 10 A metaanalysis of 12 studies and 510 critical limb ischemia patients demonstrated improved ankle-brachial index, pain score, pain-free walking distance, and transcutaenous oxygen measurements but no difference in amputation rates when only placebo-controlled trials were considered. 9 Mesenchymal stem cells (MSCs) and hematopoietic stem cells are two prominent progenitor cells that are useful in regenerative medicine. Hematopoietic stem cells are thought to give rise to two prominent subgroups of circulating progenitor cells, endothelial progenitor cells and circulating angiogenic cells (CACs). The endothelial progenitor cells become endothelial cells (ECs), whereas CACs have been described as myeloid hematopoietic progenitor cells, or cells that secrete paracrine factors to support angiogenesis. Thus, CACs function similarly to MSCs. Both endothelial progenitor cells and CACs are exciting regenerative cells that are also potent stimulators of angiogenesis and probably important to maintaining vascular health. These can be captured and expanded from peripheral blood, but unfortunately, they become relatively depleted with aging and disease states. 11 In contrast,
we and others have recently demonstrated that MSCs from PAD patients can be expanded to the numbers needed for clinical trial. 12, 13 MSCs are a particularly promising cell for PAD therapies. [14] [15] [16] MSCs exist naturally and can be harvested and rapidly expanded from many tissues, including the bone marrow (BM), adipose tissue, blood, and liver. 17, 18 Whereas MSCs can differentiate into multiple cell lines in vitro, it is now generally accepted that in vivo, MSCs function as pericyte cells that support vascular regeneration and paracrine activity of surrounding cells. 19 The two most common sites for harvesting of MSCs in PAD trials have been the BM and the adipose tissue, but it is not known whether BM-MSCs and adipose tissue-derived (ATD)-MSCs may function better in a given patient or if either is preferable under certain disease states, like diabetes and PAD. Because there are limited reports in the literature of human diabetic MSCs (dMSCs) in PAD patients, 13 the first objective of this work was to test for differences in expansion capacity and angiogenic activity in both BM-and ATD-dMSCs harvested from amputated limbs. The second objective was to investigate what cell signaling cascades may be important in dMSCs and whether these pathways are reversible by supplementing culture conditions with growth factors. We have previously demonstrated that the truncated expansion capacity of dMSCs can be significantly improved by supplementing culture media with pooled human platelet lysate (PL). 12 When examining the prominent growth factors in PL that may be important, we identified that epidermal growth factor (EGF) is one of the more prominent growth factors in PL. 20 EGF is an attractive target because it activates both the AKT and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) signaling pathways, which promote cell survival, proliferation, and sustained paracrine activity. 21 We hypothesize that dMSCs from PAD patients have a defect in EGF receptor (EGFR) pathways that may be reversible with growth factor supplementation.
METHODS
Cell culture and expansion Informed consent was obtained under an Institutional Review Board-approved protocol. BM-and ATD-dMSCs were harvested from six amputated limbs of five patients with diabetes and PAD. BM-dMSCs were harvested from Recommendation: Strategies using platelet lysate or promoting activity of the epidermal growth factor pathway may enhance stem cell function and thus use of stem cell therapy for limb salvage in diabetic patients.
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the transected tibial bones of the amputated limbs.
Briefly, the BM was flushed with 50 mL of a-Dulbecco modified Eagle medium, centrifuged, resuspended, and plated for culture in standard media with 10% fetal bovine serum (FBS). ATD-dMSCs were harvested from the subcutaneous fat from the calf of the amputated limbs and digested with 0.15% collagenase solution (Gibco, Grand Island, NY). The resulting solution was filtered, mixed with growth media (Genlantis, San Diego, Calif) and 10% FBS (Atlanta Biologicals Inc, Flowery Branch, Ga), and centrifuged, and the cell pellets were plated. MSCs were passaged before confluence weekly. PL and healthy donor MSCs were generously donated by the Galipeau laboratory.
Immunophenotype profiles of MSCs
BM-and ATD-dMSCs were stained for the expression of standard MSC antibodies CD105, CD90, and CD73 and human leukocyte antigen 1 (BD Biosciences, Franklin Lakes, NJ) and quantified using fluorescence-activated cell sorting with flow cytometry according to the methods published by the International Society for Cellular Therapy. 22 Marker expression was quantified as mean fluorescence intensity (MFI) fold change over control and was compared between BM-and ATD-dMSCs.
Population doubling BM-MSCs and ATD-MSCs were serially cultured from passage 4 onward with standard culture medium, and population doubling was calculated from weekly cell counts out to senescence. Population doublings were calculated by dividing the number of days that the cells were allowed to grow by the doubling time, and the cumulative population doubling times were calculated by adding weekly population doublings as published. 23 
Secretome analysis
The secretome from BM-and ATD-dMSCs of five patients (six limbs) was quantified through their conditioned media (CM) during passages 3 to 7. Measurement of angiogens and chemokines was performed using Luminex technology by the Human Immune Monitoring Center at Stanford University. The culture medium without cells served as the background control. The MFI of each protein was averaged for all patients, and the relative increase of each protein in the CM was calculated. An increase of 1.4 above background was considered significant. These values were then compared between the CM of BM-MSCs and ATD-MSCs using paired t-test.
Western blot analysis
BM-dMSCs were cultured under standard conditions (5% FBS plus 10 ng/mL fibroblast growth factor 2 [FGF2]), 5% PL, or 5% FBS plus 10 ng/mL EGF. Western blot analyses were then performed on dMSC lysates for AKT/pAKT, ERK1/2/ pERK1/2, and EGFR/pEGFR. Glyceraldehyde-3-phosphate dehydrogenase was the control protein. Antibodies were purchased from Cell Signaling Technology (Danvers, Mass). Healthy donor MSCs collected under a separate Institutional Review Board-approved protocol were used as control cells.
MSC invasion
To quantify MSC activity in three dimensions, MSC pellets were embedded in fibrin gels as previously described. 24 Cell invasion into the gel from the pellets was quantified by serial digital photography at a magnification of 4Â under bright-field microscopy during 3 days. Cell invasion was quantified by semiautomatic segmentation (MAT-LAB, Natick, Mass), and the average invasion distance was calculated. The experiments were replicated at least twice with similar results between groups.
Angiogenic activity of MSCs
Chemotactic activity of MSC CM on ECs. Cell migration was quantified using a modified Boyden chamber with Transwell inserts (Sigma-Aldrich, St. Louis, Mo) as described before. 25 Briefly, the wells were equilibrated with 600 mL of OptiMEM and incubated at 37 passages 4-6) were plated in EC growth medium at 20,000/insert. The lower wells were filled with pooled CM from BM-MSCs or ATD-MSCs. Results were compared with positive control (EC growth medium) and negative control (quiescent medium with 0.5% FBS). After 24-hour incubation, the tops of the inserts were wiped clean with a cotton-tipped applicator and the inserts were fixed with cold methanol, rinsed with phosphate-buffered saline, and stained with crystal violet solution (SigmaAldrich). There were six inserts per group, and each insert was analyzed in five distinct segments using a brightfield microscope at 20Â. The ECs that migrated were counted in a blinded fashion, and experiments were replicated at least twice with similar results. Mitogenic activity of MSC CM. HUVECs in passages 4 to 6 were cultured with complete growth medium on a 96-well plate to 80% confluence during 3 days. The medium was then changed to quiescent medium for 24 hours to synchronize their cell cycle. ECs were then stimulated for 48 hours with either BM-or ATD-MSC CM. The positive and negative control groups were the same as chemotaxis experiments. Proliferation was quantified fluorescently using CellTiter 96 Aqueous reagent (Promega, Madison, Wisc). Four wells were used for each group, and the experiments were replicated three times.
Co-culture angiogenic assay. A three-dimensional coculture EC sprouting assay was performed as published by co-culturing PKH-stained HUVECs (PKH: red; Sigma) with BM-MSCs or ATD-MSCs at 1:1 ratio (5 Â 10 5 cells/mL).
The resulting cell pellets were then entrapped within a fibrin hydrogel with a nylon mesh ring (Sefar, Buffalo, NY) support and cultured in 24-well plates containing standard growth medium (Corning Inc, Corning, NY). EC sprouting was quantified by fluorescent microscopy at a magnification of 4Â during 3 days and expressed as a ratio of EC sprouting in co-culture with MSCs divided by that of the EC-alone pellet.
Statistics
Experimental data are presented as the mean 6 standard deviation. Normality was analyzed using D'Agostino-Pearson test. Two-tailed, paired Student test was used to compare data between BM-MSCs and ATD-MSCs within each limb, and grouped data were analyzed by analysis of variance. Kruskal-Wallis test was used for data that were not normally distributed. GraphPad (version 6.0; GraphPad Software Inc, La Jolla, Calif) was used for the analysis. P values <.05 were considered significantly different.
RESULTS
BM-and ATD-dMSCs were successfully expanded from all limbs. There were no active smokers in this cohort, and their glucose levels were well controlled (Table) .
MSC immunophenotyping
Fluorescence-activated cell sorting was used to identify the proper MSC cell markers on our BM-and ATDdMSCs. Both MSC populations expressed the appropriate surface markers including CD90, CD105, human leukocyte antigen 1, and CD73, with low expression of CD45 and CD34 (Fig 1) .
Population doubling BM-and ATD-MSCs had similar passage-specific and cumulative population doublings from passages 4 to 11 and entered senescence after passage 11 (Fig 2) .
Secretome analysis
EGF was not expressed in the secretome of either the BM-or ATD-dMSCs (MFI < 1). However, there was robust expression of potent angiogens that was similar in both BM-and ATD-MSCs: vascular endothelial growth factor, fold increase of 22 6 8 .9 and 21.6 6 9.3; and monocyte chemoattractant protein 1, fold increase of 69.2 6 40 and 62.4 6 36.3 (Fig 3) . A complete listing of chemokines in the CM that were secreted is provided in the Supplementary Table (online only) .
Western Blot analysis
Given the similar secretome and angiogenic function between ATD-dMSCs and BM-dMSCs, we chose to restrict Western blot analysis to BM-dMSCs because we had normal healthy controls that had been immunophenotyped for BM-MSCs but not for ATD-MSCs. PL supplementation of healthy MSCs and dMSCs improved AKT expression 1.5 to 7.5 times above that of FBS plus FGF2. In dMSCs, PL increased phosphorylation of AKT to the levels seen in healthy MSCs under both FBS plus FGF2 and PL conditions. However, dMSCs did not have ). An increase of 1.4 above background was considered significant. A, Secretion of epidermal growth factor (EGF) in the media of both BM-MSCs and ATD-MSCs was negligible. B, Hepatocyte growth factor (HGF) had a significant increase in the media of both BM-MSCs and ATD-MSCs, and there were no differences between MSC populations. C, Monocyte chemoattractant protein 1 (MCP-1) had a significant increase in the media of both BM-MSCs and ATD-MSCs, and there were no differences between MSC populations. D, Vascular endothelial growth factor (VEGF) had a significant increase in the media of both BM-MSCs and ATD-MSCs, and there were no differences between MSC populations. Data analyzed using a two-tailed, paired Student test. No significant difference for any comparisons (P > .05).
augmented ERK1/2 phosphorylation with PL (Fig 4) . Since EGF is abundantly expressed in PL, 20 we then performed a dose-response curve with increasing concentrations of EGF (0-1 mm). Although increasing EGF dosages increased the ratio of pEGFR/EGFR, we chose 10 ng/mL as it approximated the EGF level in PL (w2 ng/mL) and demonstrated an increase in both pEGFR and pERK1/2 ( Supplementary Fig, online only) . In comparing EGF with PL supplementation at early time points (30 and 60 minutes), pAKT was increased with PL over EGF, but pERK1/2 was not different (Fig 5) .
MSC invasion
MSC invasion from all specimens increased with time during 3 days in both the BM-and ATD-dMSCs (Fig 6,  A) . However, there were individual differences in invasion length and relative chemokine concentrations that varied between BM-and ATD-dMSCs among limbs (Fig 6,  B1-B6 ). BM-and ATD-MSCs each had greater invasion distances in two limbs, and dMSCs from the final two limbs did not have differences in invasion lengths between BM-and ATD-dMSCs. There were not consistent differences in chemokines that associated with greater invasion distance in these dMSCs.
Angiogenic capacity
MSCs' chemotactic and mitogenic activity on ECs. The CM from both BM-and ATD-dMSCs stimulated similar HUVEC chemotaxis that was similar to EC growth medium (positive control) and significantly greater (P < .02) than the negative control (quiescent medium). Similarly, CM from BM-and ATD-dMSCs stimulated significantly greater (P < .04) EC proliferation over that of the negative control (quiescent medium; Fig 7) . MSCs stimulate EC sprouting in three-dimensional co-culture assay. To test in vitro the angiogenic effect of dMSCs on ECs, a co-culture assay (1:1 dMSC:EC) was performed (Fig 8, A) . Here, both BM-and ATD-dMSCs cocultured with ECs led to significantly longer EC sprouts than EC-alone cell pellets (day 3: 148. 4 ; Fig 8, B) . 
DISCUSSION
There are three major findings from this work. First, neither BM-nor ATD-dMSCs expressed EGF in their secretome. This is in contrast to the literature for MSCs. 26 We have now published that EGF expression can be elicited in dMSCs by elevated glucose conditions, 27 so this appears to be a modifiable problem in dMSCs that could be intentionally manipulated in cell culture. Second, PL appears to function at least in part by increasing AKT signaling pathways in dMSCs. Third, both BM-and ATD-dMSCs have similar secretomes and promote EC migration, proliferation, and sprouting in vitro to similar degrees. Cumulatively, we found that AKT signaling in dMSCs is improved with PL, which provides EGF and also provides a number of other nutritive factors compared with EGF alone. We were somewhat surprised to find that neither the BM-dMSC nor the ATD-dMSC secretomes had differences in angiogenic growth factor concentrations. We expected to find consistent individual differences in the secretome that correlated with greater (or lesser) dMSC invasion lengths. Our results suggest that it is not a particular growth factor but rather a certain combination of growth factors (eg, vascular endothelial growth factor, hepatocyte growth factor, monocyte chemoattractant protein 1) that are all expressed to a certain degree in dMSCs. These angiogens have previously been found to be critical to the paracrine activity of MSCs in tissue regeneration and angiogenesis. [28] [29] [30] Excitingly, dMSCs' angiogenic activity is similar to that reported by Ma et al, 31 who compared the angiogenic capacity of BM-MSC/EC or ATD-MSC/EC co-cultures using human cells from young and healthy donors (n ¼ 4). Here, they reported that MSCs improved EC sprouting, similar to our results. The role of EGF in dMSCs is not perfectly clear in this manuscript. Whereas the lack of EGF in the dMSC secretome likely contributes to the early senescence (passage 11) seen in our MSCs, the addition of exogenous EGF did not replicate the benefits of PL in AKT signaling. We did demonstrate in our previous publication that PL improved expansion of dMSCs, but it did not recover to the levels seen in healthy MSCs. 12 This suggests that any rejuvenation efforts on dMSCs may not return them to the same phenotype as healthy donor MSCs. We intentionally restricted this work to the function of dMSCs because this group has both the greatest need of regenerative therapies and the greatest defect in expansion capacity in our initial study. 12 However, these results may not be generalizable to all dMSCs or all MSCs from patients with diabetes and PAD. The patients in this study all had similar degrees of ischemia, but they also had well-controlled diabetes and were not active smokers; only two patients required interval amputation after guillotine for active infection. Perhaps because of these similarities, there were no significant differences identified in the secretome or angiogenic activity between the BM-and ATD-dMSCs. Notwithstanding, there were some differences in the degree of MSC invasion identified among different limb specimens. Unfortunately, these differences were not consistently in favor of either BM or ATD, nor did they correlate with a certain growth factor. Thus, both BM-and ATD-dMSCs will probably have similar regenerative capacity in nonsmoking patients with well-controlled diabetes.
EC+BM-MSC-CM EC+ATD-MSC-CM EC+ quiescent media EC+BM-MSC-CM EC+ATD-MSC-CM EC+
Still, there are a number of limitations to this work that deserve discussion. Previous studies in a diabetic PAD population had similar but smaller sample sizes (Smadja et al, 32 n ¼ 1; Gremmels et al, 13 n ¼ 3;
Brewster et al, 12 n ¼ 4), making this the largest study to date. Whereas the sample size for human cells is not always included in manuscripts similar to ours, [33] [34] [35] there are a number of publications that have sample sizes similar to ours. [36] [37] [38] Thus, we think our sample size is a reasonable number but do not exclude the possibility that small differences between the BM-and ATDdMSCs could be identified with a larger sample size. and analyzed with analysis of variance. Day 3 data were determined to be non-normal and were analyzed using Kruskal-Wallis test. *Corresponds to P < .05.
Second, although we have demonstrated that BM-and ATD-dMSCs stimulate angiogenesis and have a similar secretome, there may be unique aspects of the dMSCs' angiogenic secretome that could limit the degree or durability of vascular regeneration in vivo. 27 The dMSC donors in this study had well-controlled diabetes and were not active smokers. Poorly controlled diabetic patients or active smokers would likely have even more pronounced cell signaling defects and limitations in expansion capacity, but this is not known. Whereas it is possible that the BM-and ATD-dMSCs are "primed" by different conditions, such as the degree of infection or ischemia, it is striking to see such similarity in the secretome and angiogenic activity between these two groups.
Here, the two limbs that were associated with active infection underwent guillotine amputation before the definitive amputation; this may have lessened the impact of infection on these dMSCs. Furthermore, despite publications suggesting that hypoxic conditions can stimulate a proangiogenic secretome profile and enhance BM-MSC expansion, 39, 40 preliminary data in our laboratory have not found this to be true in MSCs from either diabetic or nondiabetic PAD patients. Finally, our healthy donor MSCs were cultured from BM of the iliac crest of donor patients, but our dMSCs were from the tibia of amputated specimens. Although this could lead to an unfair comparison group, the literature to date suggests otherwise. There is a report in the literature of patients with rheumatoid arthritis that identified a relative decrease in colony-forming units in the tibia with a possible deficit in osteogenic differentiation. 41 However, Narbona-Carceles et al 42 demonstrated that BM-MSCs from the iliac crest and those derived from the metaphysis of both the distal femur and proximal tibia have similar phenotype and differentiation potential. Interestingly, many preclinical animal models use the limb long bones for MSC harvest, 43,44 and our previous publication from MSCs harvested from the tibia of amputated specimens was similar to the only other two publications of MSCs harvested from the iliac crests of PAD patients.
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CONCLUSIONS
Because of the increasing prevalence of diabetes coupled with improved longevity of patients with cardiovascular disease (more patients with PAD and diabetes at risk of critical limb ischemia living longer), the vascular complications of diabetes and subsequent major amputation rates are likely to be an increasing problem in the United States.
14 Whereas the benefit of cell therapies in clinical trials to date has not been overwhelming, cellular therapies (particularly MSCs) remain a modality with promise. 9 Here we have identified that EGF expression and AKT signaling defects in dMSCs can be reversed with PL. Because our data support robust angiogenic activity of both BM-and ATD-dMSCs, exogenous EGF or PL strategies may be an effective strategy for not only improving dMSC expansion but also prolonging dMSC survival for cellular therapies. Additional material for this article may be found online at www.jvascsurg.org.
INVITED COMMENTARY
Michael C. Dalsing, MD, Indianapolis, Ind Preventing the advancement of or, better yet, reversing peripheral vascular occlusive disease could save many limbs and provide a better quality of life for our patients. The "magic bullet" of an individual agent placed locally to change the milieu sufficiently to improve collateral vascular development or to stimulate angiogenesis has not been successful to date. However, providing cells that can change the local milieu by providing a slurry of beneficial agents is more promising. Mesenchymal stem cells (MSCs) can provide stromal support and paracrine effects of potential benefit. Unfortunately, one group of patients who could benefit most are those with diabetes, and yet their MSCs (dMSCs) have a deficient expansion capacity. This paper tests the hypothesis that dMSCs have a reversible defect in the epidermal growth factor (EGF) receptor pathway that may blunt cell growth and survival. Human platelet lysate (PL), known to be rich in several growth factors including EGF, might reverse this deficiency, as might EGF alone. It tests whether dMSCs can provide angiogenic stimulus of human umbilical vein endothelial cells (ECs) and, therefore, be a viable regenerative treatment.
The study demonstrates that MSCs from the bone marrow and adipose tissue of limbs of well-controlled, nonsmoking diabetic patients have similar population doublings and entered senescence after passage 11, confirming deficient expansion capacity. In addition, dMSCs do not express EGF in their secretome while demonstrating robust expression of other angiogens. Supplementing the dMSCs with PL increased phosphorylation of AKT to healthy MSC levels, whereas providing EGF alone increased only phosphorylated extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) to similar levels as that of PL supplementation. MSC invasion increased over time, but there were inconsistent differences of invasion length and chemokine concentration across MSC types and patients. Both cell types were able to stimulate EC proliferation like standard EC growth media and in co-culture demonstrated longer EC sprouts.
In contrast to past literature, this study confirms a lack of EGF expression by dMSCs, providing a deficiency that is cell culture modifiable. Adding EGF increased phosphorylated ERK1/2 levels but not pAKT levels, whereas PL increased both, which may be important because both AKT and ERK1/2 signaling pathways promote cell survival, proliferation, and sustained paracrine activity. The lack of EGF may explain the early senescence noted in the study, but exogenous EGF certainly does not fully correct deficient signaling pathways, whereas PL does better but likely not totally in considering prior studies by the same authors. Both types of dMSCs promote EC proliferation and sprouting, which supports the regenerative benefits of these cells if sufficient numbers for local injection are available.
This study has limitations regarding sample size, potential lack of generalization (the population was nonsmoking, well-controlled diabetic patients), and potential bias because the control MSCs were from the iliac crest whereas the experimental MSCs were from the tibia. Provided is some detailed explanation as to how these limitations can be interpreted. Overall, this study is another step forward in the basic science wheel of evidence that will eventually lead to a clinical advancement in regenerative medicine aimed at limb salvage. RaƟo of p-ERK 1/2 to total ERK 1/2 Supplementary Fig (online only) . Dose-response curves of epidermal growth factor (EGF) in healthy mesenchymal stem cells (MSCs), 24 hours. Increasing pEGFR/EGFR ratios with increasing dosages of EGF; 10 ng/mL EGF had the optimal pERK1/2 to ERK1/2 ratio in healthy MSCs. EGFR, Epidermal growth factor receptor; ERK1/2, extracellular signal-regulated protein kinases 1 and 2.
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